NCT05528315View on ClinicalTrials.gov

SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

June 26, 2023

Study Completion Date

September 13, 2023

Conditions
MDD
Interventions
DRUG

ABX-002

ABX-002

DRUG

Placebo

Placebo

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Autobahn Therapeutics, Inc.

INDUSTRY

NCT05528315 - SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects | Biotech Hunter | Biotech Hunter